GleamWall
中文EN

DMAC DiaMedica Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1401040 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-26.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-100.2%
ROA-86.3%
ROIC (approx.)-94.2%
Asset turnover—

Leverage & solvency

Liabilities / assets20.7%
Debt / equity0.00x
Current ratio4.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$24.61M$19.06M
SG&A expense$9.78M$7.62M
Operating income-$34.40M-$26.68M
Pretax income-$32.74M-$24.41M
Income tax$28,000$30,000
Net income-$32.77M-$24.44M
EBITDA-$34.35M-$26.64M
EPS (basic)-0.70-0.60
EPS (diluted)——
Balance sheet
Cash & equivalents$15.65M$3.02M
Short-term investments$44.24M$41.12M
Receivables$258,000$236,000
Current assets$60.63M$44.61M
PP&E, net$145,000$148,000
Total assets$61.37M$46.34M
Current liabilities$5.13M$5.39M
Total liabilities$5.26M$5.63M
Shareholders' equity$56.11M$40.72M
Shares outstanding53.74M42.82M
Cash flow statement
Operating cash flow-$29.06M-$22.08M
Capital expenditure$40,000$25,000
Free cash flow-$29.10M-$22.10M
Investing cash flow-$2.19M$8.56M
Financing cash flow$43.88M$11.99M
Depreciation & amortization$43,000$39,000
Stock-based compensation$3.85M$2.08M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.